Table 2:
Assigned Dose Levels and Rates of Dose Limiting Toxicities (n=10 evaluable patients)
| Dose Level | Dose | Number Treated | Number with DLT | DLT | Prior Probability of DLT | Posterior Probability of DLT | 95% HPD Credible Interval |
|---|---|---|---|---|---|---|---|
| −1 | 20C, 800G | 4 | 1 | Grade 3 thrombocytopenia (Day 15) |
0.05 | 0.27 | 0.06 – 0.46 |
| 1 | 20C, 1000G | 5 | 2 | Grade 3 ALT elevation (Day 8) Grade 3 AST/ALT elevation (Day 15) |
0.10 | 0.36 | 0.14 – 0.57 |
| 2 | 40C, 1000G | 1 | 1 | Grade 3 ALT elevation and Grade 3 thrombocytopenia (Day 22) |
0.15 | 0.43 | 0.21 – 0.65 |
| 3 | 60C, 1000G | 0 | 0 | 0.20 | 0.49 | 0.29 – 0.70 | |
| 4 | 80C, 1000G | 0 | 0 | 0.25 | 0.54 | 0.35 – 0.73 |
C: Cabozantinib, dose in mg; G: Gemcitabine, dose in mg/m2; HPD: Highest Posterior Density